Ísrael - hebreska - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine

Ísrael - hebreska - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine

Ísrael - hebreska - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine

Ísrael - hebreska - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Ísrael - hebreska - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Ísrael - hebreska - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Ísrael - hebreska - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Ísrael - hebreska - Ministry of Health

sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat

Ísrael - hebreska - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 1 mg - melatonin

Ísrael - hebreska - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 5 mg - melatonin